|Free Dividend Report|
|Stock Splits Calendar|
|MBRX Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|Stock Message Boards|
Moleculin Biotech (MBRX) has 1 split in our MBRX split history database. The split for MBRX took place on February 01, 2021. This was a 1 for 6 reverse split, meaning for each 6 shares of MBRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as Moleculin Biotech conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MBRX split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Moleculin Biotech shares, starting with a $10,000 purchase of MBRX, presented on a split-history-adjusted basis factoring in the complete MBRX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-41.43%|
|About Moleculin Biotech|
|Moleculin Biotech is a pharmaceutical company focused on the treatment of resistant cancers. Co.'s technologies are based on discoveries made at MD Anderson Cancer Center (MD Anderson). Co.'s primary product candidates is Annamycin, for which Food and Drug Administration allowed an Investigational New Drug Application to go into effect for a Phase 1/2 trial for the treatment of relapsed or refractory acute myeloid leukemia. Co. also has a license agreement with MD Anderson pursuant to which Co. had been granted a license for the patent and technology rights related to its WP1066 Portfolio and its close analogs, molecules targeting the modulation of primary oncogenic transcription factors. According to our MBRX split history records, Moleculin Biotech has had 1 split.|
|MBRX Split History Table|
|02/01/2021||1 for 6|
|Healthcare Stock Splits|
|MBRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: MBRX shares outstanding history